Literature DB >> 12063083

The L-3,4-dihydroxyphenylalanine transporter in human and rat epithelial intestinal cells is a type 2 hetero amino acid exchanger.

Sónia Fraga1, Maria Paula Serrão, Patrício Soares-da-Silva.   

Abstract

Information on the intestinal transport of L-3,4-dihydroxyphenylalanine (L-DOPA) is scarce. We present here the functional characteristics and regulation of the apical inward L-DOPA transport in two intestinal epithelial cell lines (human Caco-2 and rat IEC-6). The inward transfer of L-DOPA and L-leucine was promoted through an energy-driven system but with different sensitivity to extracellular Na(+) concentration: a minor component of L-leucine uptake (approximately 25%) was found to require extracellular Na(+) in comparison with L-DOPA transport which was Na(+)-independent. L-DOPA and L-leucine uptake was insensitive to N-(methylamino)-isobutyric acid, but competitively inhibited by 2-aminobicyclo(2,2,1)-heptane-2-carboxylic acid (BCH). L- and D-neutral amino acids, but not acidic and basic amino acids, markedly inhibited L-DOPA and [(14)C]L-leucine accumulation in both cell lines. The [(14)C]L-DOPA and [14C]L-leucine outward were markedly increased by L-leucine and BCH present in extracellular medium, but not by L-arginine. In both cell lines, L-DOPA transport was stimulated by acidic pH in comparison with [(14)C]L-leucine inward which was pH-independent. In conclusion, it is likely that system B(0) might be responsible for the Na(+)-dependent uptake of L-leucine in Caco-2 and IEC-6 cells, whereas sodium-independent uptake of L-leucine and L-DOPA may include system type 1 and type 2 L-amino acid transporter (LAT1 and LAT2), the activation of which results in trans-stimulation of substrates outward transfer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063083     DOI: 10.1016/s0014-2999(02)01416-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs.

Authors:  Evan Augustyn; Karissa Finke; Arik A Zur; Logan Hansen; Nathan Heeren; Huan-Chieh Chien; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2016-04-11       Impact factor: 2.823

2.  LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.

Authors:  Arik A Zur; Huan-Chieh Chien; Evan Augustyn; Andrew Flint; Nathan Heeren; Karissa Finke; Christopher Hernandez; Logan Hansen; Sydney Miller; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2016-09-03       Impact factor: 2.823

3.  Genomic regulation of intestinal amino acid transporters by aldosterone.

Authors:  João S Amaral; Maria João Pinho; Patrício Soares-da-Silva
Journal:  Mol Cell Biochem       Date:  2008-03-18       Impact factor: 3.396

4.  Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1).

Authors:  Huan-Chieh Chien; Claire Colas; Karissa Finke; Seth Springer; Laura Stoner; Arik A Zur; Brooklynn Venteicher; Jerome Campbell; Colton Hall; Andrew Flint; Evan Augustyn; Christopher Hernandez; Nathan Heeren; Logan Hansen; Abby Anthony; Justine Bauer; Dimitrios Fotiadis; Avner Schlessinger; Kathleen M Giacomini; Allen A Thomas
Journal:  J Med Chem       Date:  2018-08-10       Impact factor: 7.446

5.  The Effects of Prodrug Size and a Carbonyl Linker on l-Type Amino Acid Transporter 1-Targeted Cellular and Brain Uptake.

Authors:  Brooklynn Venteicher; Kasey Merklin; Huy X Ngo; Huan-Chieh Chien; Keino Hutchinson; Jerome Campbell; Hannah Way; Joseph Griffith; Cesar Alvarado; Surabhi Chandra; Evan Hill; Avner Schlessinger; Allen A Thomas
Journal:  ChemMedChem       Date:  2020-12-11       Impact factor: 3.466

Review 6.  Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.

Authors:  Aravind Mittur; Suneel Gupta; Nishit B Modi
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

Review 7.  Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Authors:  Alberto J Espay; Fernando L Pagan; Benjamin L Walter; John C Morgan; Lawrence W Elmer; Cheryl H Waters; Pinky Agarwal; Rohit Dhall; William G Ondo; Kevin J Klos; Dee E Silver
Journal:  Neurol Clin Pract       Date:  2017-02

Review 8.  A G-Protein Coupled Receptor and Macular Degeneration.

Authors:  Anna G Figueroa; Brian S McKay
Journal:  Cells       Date:  2020-04-08       Impact factor: 6.600

Review 9.  Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease.

Authors:  Sebastiaan P van Kessel; Sahar El Aidy
Journal:  Front Neurol       Date:  2019-10-15       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.